# Dapagliflozin After Transcatheter Aortic Valve Implantation

Study · id `cardio:ct-nct04696185` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04696185](<https://clinicaltrials.gov/study/NCT04696185>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04696185

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1257 participants.

## Technical summary

Registry record NCT04696185. Randomized; single masking; primary purpose treatment. Start 2021-01-27 (actual); primary completion 2024-12-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1257 participants (enrolled count; ClinicalTrials.gov record NCT04696185, source copy `cardio:ctgov-nct04696185-2025-01-10`, retrieved 2026-11-18)
- Started: 2021-01-27 (actual) (ClinicalTrials.gov record NCT04696185, source copy `cardio:ctgov-nct04696185-2025-01-10`, retrieved 2026-11-18)
- Primary completion: 2024-12-29 (actual) (ClinicalTrials.gov record NCT04696185, source copy `cardio:ctgov-nct04696185-2025-01-10`, retrieved 2026-11-18)
- Completion: 2024-12-30 (actual) (ClinicalTrials.gov record NCT04696185, source copy `cardio:ctgov-nct04696185-2025-01-10`, retrieved 2026-11-18)
- Countries: Spain (ClinicalTrials.gov record NCT04696185, source copy `cardio:ctgov-nct04696185-2025-01-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04696185-2025-01-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: Dapagliflozin After Transcatheter Aortic Valve Implantation
- Acronym: DapaTAVI
- Condition: Aortic Stenosis
- Condition: Transcatether Aortic Valve Implantation
- Intervention (Drug): Dapagliflozin 10 MG
- Lead sponsor: Spanish Society of Cardiology
- Lead sponsor class: OTHER
- Collaborator: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Spanish Society of Cardiology (`cardio:org-spanish-society-of-cardiology`)
- Registry lists this organization as a collaborator: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (`cardio:org-fundacion-centro-nacional-de-investigaciones-0f9f16`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation (`cardio:pubmed-40162639`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation (`cardio:pubmed-41062227`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Influence of diabetes mellitus on dapagliflozin response after transcatheter aortic valve replacement (TAVR): insights from the DAPA-TAVI trial (`cardio:pubmed-43004293`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2d6814679ec99c002b39527ee8dc61b874bde5bf22f27523ceeb7d66bb2ae01b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
